Last reviewed · How we verify
Adipose-Derived Mesenchymal Stem Cells
Adipose-derived mesenchymal stem cells modulate immune responses and promote tissue repair through paracrine signaling and differentiation into multiple cell types.
Adipose-derived mesenchymal stem cells modulate immune responses and promote tissue repair through paracrine signaling and differentiation into multiple cell types. Used for Orthopedic injuries, Autoimmune diseases, Wound healing.
At a glance
| Generic name | Adipose-Derived Mesenchymal Stem Cells |
|---|---|
| Sponsor | Steminent Biotherapeutics Inc. |
| Drug class | cell therapy |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
These cells secrete various growth factors and cytokines that can reduce inflammation, promote angiogenesis, and support the regeneration of damaged tissues. They also have the potential to differentiate into osteocytes, chondrocytes, and adipocytes, contributing to tissue healing and regeneration.
Approved indications
- Orthopedic injuries
- Autoimmune diseases
- Wound healing
Common side effects
- Infection
- Local pain
Key clinical trials
- Evaluation of Allogenic Mesenchymal Stem Cell (MSC) Injection Therapy for Refractory Graft-versus-Host Disease (GVHD) Unresponsive to Conventional Treatments (PHASE2)
- Anterior Cruciate Ligament (ACL) Reconstruction With Autologous Fat Pad Derived Mesenchymal Stem Cells (PHASE1)
- Autologous SVF Therapy for Type 2 Diabetes (NA)
- Stem Cells for Erectile Dysfunction Post RALP (PHASE1, PHASE2)
- Safety and Efficacy of Autologous Adipose-derived Mesenchymal Stem Cells Therapy in Adults With Atrophic Scars (PHASE1, PHASE2)
- "An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs (Hope Biosciences - Adipose Derived Mesenchymal Stem Cells) for the Treatment of Multiple System Atrophy."
- Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS) (PHASE2)
- Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |